As per our finding that MAPK-mutated HNSCC tumors are endowed with inherently high CD8+ T-cell–inflamed immunoactive tumor microenvironment with high endogenous cytolytic activity, we analyzed HNSCC patient outcomes from the Samstein-ICI HNSCC dataset. The gene discussed is CD8A; the disease is neoplasm.